Angiogenic factors could help us to define patients obtaining complete response with undetectable minimal residual disease in untreated CLL patients treated by FCR: results from the CLL2010FMP, a FILO study

References

• Ferrara N, Chen H, Davis-Smyth T, et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med. 1998;4(3):336–340.
   PubMed Web of Science ®Google Scholar
• Sherer DM, Abulafia O. Angiogenesis during implantation, and placental and early embryonic development. Placenta. 2001;22(1):1–13.
   PubMed Web of Science ®Google Scholar
• Li J, Zhang YP, Kirsner RS. Angiogenesis in wound repair: angiogenic growth factors and the extracellular matrix. Microsc Res Tech. 2003;60(1):107–114.
   PubMed Web of Science ®Google Scholar
• Anderson H, Price P, Blomley M, et al. Cancer Research Campaign PKPDTAC. Measuring changes in human tumour vasculature in response to therapy using functional imaging techniques. Br J Cancer. 2001;85(8):1085–1093.
   PubMed Web of Science ®Google Scholar
• Kini AR, Kay NE, Peterson LC. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia. 2000;14(8):1414–1418.
   PubMed Web of Science ®Google Scholar
• Peterson L, Kini AR. Angiogenesis is increased in B-cell chronic lymphocytic leukemia. Blood. 2001;97(8):2529.
   PubMed Web of Science ®Google Scholar
• Kay NE, Bone ND, Tschumper RC, et al. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia. 2002;16(5):911–919.
   PubMed Web of Science ®Google Scholar
• Ding W, Knox TR, Tschumper RC, et al. Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. Blood. 2010;116(16):2984–2993.
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Katz BZ, Lipsky A, et al. Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. Hematol Oncol Clin North Am. 2013;27(2):173–206.
   PubMed Web of Science ®Google Scholar
• Maffei R, Martinelli S, Santachiara R, et al. Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia. Blood. 2010;116(4):584–592.
   PubMed Web of Science ®Google Scholar
• Redondo-Munoz J, Ugarte-Berzal E, Garcia-Marco JA, et al. Alpha4beta1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood. 2008;112(1):169–178.
   PubMed Web of Science ®Google Scholar
• Buggins AG, Levi A, Gohil S, et al. Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9. Br J Haematol. 2011;154(2):216–222.
   PubMed Web of Science ®Google Scholar
• Tout M, Gagez AL, Lepretre S, et al. Influence of FCGR3A-158V/F genotype and baseline CD20 antigen count on target-mediated elimination of rituximab in patients with chronic lymphocytic leukemia: a study of FILO group. Clin Pharmacokinet. 2017;56(6):635–647.
   PubMed Web of Science ®Google Scholar
• Dommange F, Cartron G, Espanel C, et al. CXCL12 polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukemia. FASEB J. 2006;20(11):1913–1915.
   PubMed Web of Science ®Google Scholar
• Anthony BA, Link DC. Regulation of hematopoietic stem cells by bone marrow stromal cells. Trends Immunol. 2014;35(1):32–37.
   PubMed Web of Science ®Google Scholar
• Burger JA, Kipps TJ. Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leuk Lymphoma. 2002;43(3):461–466.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, International Workshop on Chronic Lymphocytic Leukemia, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–5456.
   PubMed Web of Science ®Google Scholar
• Lepretre S, Letestu R, Dartigeas C, et al. Results of a phase II randomizing intensified rituximab pre-phase followed by standard FCR vs standard FCR in previously untreated patients with active B-chronic lymphocytic leukemia (B-CLL). CLL2010FMP (for fit medically patients): a study of the French Cooperative Group on CLL and WM (FCGCLL/MW) and the “Groupe Ouest-Est d’Etudes Des Leucémies Aigües Et Autres Maladies Du sang” (GOELAMS). Poster. 2014;124(21):3329–3329.
   Google Scholar
• Cartron G, Letestu R, Dartigeas C, et al. Increased rituximab exposure does not improve response and outcome of CLL patients after FCR. A French Innovative Leukemia Organization (FILO) study. Haematologica. 2018;103(8):e356–e359.
   PubMed Web of Science ®Google Scholar
• Letestu R, Dahmani A, Boubaya M, et al. Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia. 2021 Jun;35(6):1597–1609.
   Google Scholar
• Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15–21.
   PubMed Web of Science ®Google Scholar
• Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5(10):R80.
   PubMed Web of Science ®Google Scholar
• Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.
   PubMed Web of Science ®Google Scholar
• Liberzon A, Subramanian A, Pinchback R, et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27(12):1739–1740.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545–15550.
   PubMed Web of Science ®Google Scholar
• Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32–35.
   PubMed Web of Science ®Google Scholar
• Efron B, Tibshirani R. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat Sci. 1986;1(1):54–75.
   Google Scholar
• Efron B. Bootstrap methods: another look at the jackknife. Ann Stat. 1979;7(1):1–26.
   Web of Science ®Google Scholar
• International CLLIPIwg. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779–790.
   PubMed Web of Science ®Google Scholar
• Delgado J, Doubek M, Baumann T, et al. Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI. Am J Hematol. 2017;92(4):375–380.
   PubMed Web of Science ®Google Scholar
• Huttmann A, Klein-Hitpass L, Thomale J, et al. Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression status. Leukemia. 2006;20(10):1774–1782.
   PubMed Web of Science ®Google Scholar
• Martinelli S, Maffei R, Castelli I, et al. Increased expression of angiopoietin-2 characterizes early B-cell chronic lymphocytic leukemia with poor prognosis. Leuk Res. 2008;32(4):593–597.
   PubMed Web of Science ®Google Scholar
• Martinelli S, Kanduri M, Maffei R, et al. ANGPT2 promoter methylation is strongly associated with gene expression and prognosis in chronic lymphocytic leukemia. Epigenetics. 2013;8(7):720–729.
   PubMed Web of Science ®Google Scholar
• Maffei R, Bulgarelli J, Fiorcari S, et al. The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. Haematologica. 2013;98(7):1115–1123.
   PubMed Web of Science ®Google Scholar
• Yang J, Liu X, Nyland SB, et al. Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway. Blood. 2010;115(1):51–60.
   PubMed Web of Science ®Google Scholar
• Ho CL, Hsu LF, Phyliky RL, et al. Autocrine expression of platelet-derived growth factor B in B cell chronic lymphocytic leukemia. Acta Haematol. 2005;114(3):133–140.
   PubMed Web of Science ®Google Scholar
• Michalevicz R, Katz F, Stroobant P, et al. Platelet-derived growth factor stimulates growth of highly enriched multipotent haemopoietic progenitors. Br J Haematol. 1986;63(3):591–598.
   PubMed Web of Science ®Google Scholar
• Katz FE, Michalevicz R, Lam G, et al. Effect of platelet-derived growth factor on enriched populations of haemopoietic progenitors from patients with chronic myeloid leukaemia. Leuk Res. 1987;11(4):339–344.
   PubMed Web of Science ®Google Scholar
• Caenazzo A, Pietrogrande F, Polato G, et al. Changes in the mitogenic activity of platelet-derived growth factor(s) in patients with myeloproliferative disease. Acta Haematol. 1989;81(3):131–135.
   PubMed Web of Science ®Google Scholar
• Nara N, Tohda S, Nagata K, et al. Effect of platelet-derived growth factor on the proliferation of blast progenitors from acute myeloblastic leukemia patients. Acta Haematol. 1990;83(4):187–192.
   PubMed Web of Science ®Google Scholar
• Daynes RA, Dowell T, Araneo BA. Platelet-derived growth factor is a potent biologic response modifier of T cells. J Exp Med. 1991;174(6):1323–1333.
   PubMed Web of Science ®Google Scholar
• Shi M, Cao M, Song J, et al. PinX1 inhibits the invasion and metastasis of human breast cancer via suppressing NF-κB/MMP-9 signaling pathway. Mol Cancer. 2015;14:66.
   PubMed Web of Science ®Google Scholar
• Xia Y, Lian S, Khoi PN, et al. Chrysin inhibits tumor promoter-induced MMP-9 expression by blocking AP-1 via suppression of ERK and JNK pathways in gastric cancer cells. PLOS One. 2015;10(4):e0124007.
   PubMed Web of Science ®Google Scholar
• Vandooren J, Van den Steen PE, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit Rev Biochem Mol Biol. 2013;48(3):222–272.
   PubMed Web of Science ®Google Scholar
• Yuan HT, Khankin EV, Karumanchi SA, et al. Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol. 2009;29(8):2011–2022.
   PubMed Web of Science ®Google Scholar
• Till KJ, Spiller DG, Harris RJ, Chen H, et al. CLL, but not normal, B cells are dependent on autocrine VEGF and alpha4beta1 integrin for chemokine-induced motility on and through endothelium. Blood. 2005;105(12):4813–4819.
   PubMed Web of Science ®Google Scholar